Advertisement

Topics

Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer

06:20 EDT 6 Sep 2017 | pharmaphorum

Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC)  patients, both in first line use and a second line setting. Alecensa is taking on the established drug for ALK+...

Original Article: Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer

NEXT ARTICLE

More From BioPortfolio on "Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...